PharmaLytica 2021 Hyderabad review.

Marksans Pharma slips 4% post USFDA inspection at Goa facility


Shares of Marksans Pharma slipped 4 percent intraday Thursday after USFDA issued Form 483 with eight observations

USFDA has concluded inspection at Goa facility which took place between February 25 and March 6, 2019, resulting in a Form 483 with eight observations.

None of these observations are considered either critical or repetitive in nature. Company is highly confident of closing these expeditiously and remains committed to global standards of quality & compliance, company said in release.

The site will continue to supply to the US markets all approved ANDA's. This inspection will help company to received pending ANDA's approval already filed by it.




This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More